A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport

By W. Oliver, J. L. Shenk, M. Snaith, Caroline Russell, K. D. Plunket, N. Bodkin, M. Lewis, D. Winegar, Marcos L. Sznaidman, Millard H. Lambert and 5 more. Proceedings of the National Academy of Sciences of the United States of America, 2001

1,100 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/36e6b0c3f2760051869b06d2b96f1a57ddd89208

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. A. Chawla
2. S. Bensinger
3. J. Odegaard
4. P. Tontonoz
5. Shannon M. Reilly

In Molecular Biology

1. S. Bensinger
2. D. Moller
3. A. Chawla
4. P. Tontonoz
5. I. Tabas
6. David J. Loane
7. K. Bornfeldt
8. Alok Kumar

Citations in the corpus

• The mechanisms of action of PPARs. (2002, background): “reported that the potent and selective PPARδ agonist GW-501516 could induce a substantial increase in HDL-cholesterol levels as well as a reduction in triglyceride levels in obese Rhesus monkeys (48).”
• Emerging roles of PPARS in inflammation and immunity (2002, background): “Specific activation of PPARβ/δ increases the level of high-density lipoproteins and can beneficially alter serum lipid profiles (an increase in high-density lipoproteins and a decrease in serum triglycerides”
• Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. (2008, background): “Strikingly, cotransfection of PPARd greatly augmented IL-4’s transcriptional activity on this promoter ( 4-fold), which was not further potentiated by GW501516, a synthetic agonist of PPARd (Oliver et al., 2001) (Figure 1D).”
• Integration of metabolism and inflammation by lipid-activated nuclear receptors (2008, background): “Strikingly, administration of the synthetic ligand GW501516 to rhesus macaques resulted in a significant increase in HDL cholesterol, a decrease in LDL cholesterol and a decrease in fasting triglyceride concentration”